509 episoder
The Bio Report Levine Media Group
-
- Vitenskap
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
-
Teaching an Old Drug a New Trick to Prevent Lyme Disease
Bobby Azamian, CEO of Tarsus, discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.
-
A New Class of Cell Therapies to Target Solid Tumors
Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.
-
Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies
Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.
-
A Company Born from a Father Who Wore His Heart on His Sleeve
Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.
-
Using AI to Improve Burn Care
Pete Carlson, CEO of Spectral AI, discusses the company’s AI-driven DeepView System for assessing burns, how it provides clinicians an objective and immediate assessment of a wound’s healing potential, and how it changes outcomes for patients.
-
A Home for Biotech in the City that Never Sleeps
New York City is not the first place that comes to mind when thinking of biotech clusters, but the Big Apple has been a growing center of biomedical innovation with its mix of academic research hospitals, finance, and growing number of biopharmaceutical companies. One place that’s seeking to serve as both a home to innovative companies and facilitate collaborations is Cure, which describes itself as a healthcare innovation campus. We spoke to Seema Kumar, CEO of Cure, about how it operates, its various initiatives, and what can be done to accelerate the movement of innovative technologies from the lab to the marketplace.